CLDX (Celldex Therapeutics) Goodwill-to-Asset: 0.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CLDX Celldex Therapeutics Inc CLDX
57 GF Score
Price $35.65
GF Value $7.44
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Celldex Therapeutics Goodwill-to-Asset?

Celldex Therapeutics CLDX +1.11% 57 Goodwill-to-Asset is 0.00 as of Mar. 2026. GuruFocus rates CLDX with a GF Score™ of 57/100 and a GF Value™ of $7.44 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. Celldex Therapeutics's Goodwill for the quarter that ended in Mar. 2026 was $0.00 Mil. Celldex Therapeutics's Total Assets for the quarter that ended in Mar. 2026 was $511.25 Mil. Therefore, Celldex Therapeutics's Goodwill to Asset Ratio for the quarter that ended in Mar. 2026 was 0.00.


Celldex Therapeutics  (NAS:CLDX) Goodwill-to-Asset Explanation

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


Celldex Therapeutics Goodwill-to-Asset Related Terms


Celldex Therapeutics Goodwill-to-Asset Historical Data

* Premium members only.

The historical data trend for Celldex Therapeutics's Goodwill-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celldex Therapeutics Goodwill-to-Asset Chart

Celldex Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Goodwill-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Celldex Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Goodwill-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CLDX vs IRON, QURE, ATAI: Goodwill-to-Asset Comparison

For the Biotechnology subindustry, Celldex Therapeutics's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Celldex Therapeutics Goodwill-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celldex Therapeutics's Goodwill-to-Asset distribution charts can be found below:

* The bar in red indicates where Celldex Therapeutics's Goodwill-to-Asset falls into.


CLDX
57GF Score
Celldex Therapeutics Inc CLDX
Goodwill-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celldex Therapeutics Goodwill-to-Asset Calculation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

Celldex Therapeutics's Goodwill to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Goodwill to Asset (A: Dec. 2025 )=Goodwill/Total Assets
=0/582.983
=0.00

Celldex Therapeutics's Goodwill to Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

Goodwill to Asset (Q: Mar. 2026 )=Goodwill/Total Assets
=0/511.254
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Goodwill-to-Asset →
What does a Goodwill-to-Asset of 0.00 mean?
Celldex Therapeutics (CLDX) has a Goodwill-to-Asset of 0.00 as of Mar. 2026. Goodwill-to-Asset Ratio is the total goodwill from acquisitions divided by total assets. View historical data on Celldex Therapeutics and its competitors.
Is Celldex Therapeutics' Goodwill-to-Asset too high?
Celldex Therapeutics' current Goodwill-to-Asset is 0.00. Overall, Celldex Therapeutics has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Celldex Therapeutics' Goodwill-to-Asset compare to IRON and QURE?
Celldex Therapeutics' Goodwill-to-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Goodwill-to-Asset for a Biotechnology company?
A good Goodwill-to-Asset depends on the Biotechnology industry context. However, Goodwill-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Goodwill-to-Asset mean?
A high Goodwill-to-Asset can signal that a stock is expensive relative to its fundamentals. Goodwill-to-Asset Ratio is the total goodwill from acquisitions divided by total assets. View historical data on Celldex Therapeutics and its competitors. Celldex Therapeutics's current Goodwill-to-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celldex Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Celldex Therapeutics (CLDX) is currently considered Significantly Overvalued. The stock's GF Value™ is $7.44, compared to a current price of $35.65 — trading 379.2% above its estimated fair value. The current Goodwill-to-Asset is 0.00. Celldex Therapeutics' overall GF Score™ is 57/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Goodwill-to-Asset calculated?
Goodwill-to-Asset is calculated from a company's financial statements. For Celldex Therapeutics (CLDX), the current Goodwill-to-Asset is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Celldex Therapeutics (CLDX) Overvalued in 2026?

Based on GuruFocus' analysis, Celldex Therapeutics stock appears to be overvalued. The current stock price of $35.65 is trading 379.2% above its estimated GF Value™ of $7.44. GuruFocus considers Celldex Therapeutics to be Significantly Overvalued.

Key valuation signals for CLDX:

  • Goodwill-to-Asset: 0.00
  • GF Value™: $7.44 vs. price of $35.65 (379.2% above fair value)
  • GF Score™: 57/100 with 8 warning signs

No single metric tells the full story. See the CLDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Celldex Therapeutics Business Description

Other Exchanges TCE2:Germany
Address 53 Frontage Road, Suite 220, Perryville III Building, Hampton, NJ, USA, 08827
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
57GF Score

Get the complete analysis for CLDX

Goodwill-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$35.65
Price
$7.44
GF Value